On Tuesday, Oct. 30, Allergan, Inc. AGN will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
Based on management's projections, Allergan analysts model for earnings of $4.02 per share on sales of $3.86 billion.
Allergan reported EPS of $4.15 when it published results during the same quarter last year. Sales in that period totaled $4.03 billion. If the company were to match the consensus estimate when it reports Tuesday, EPS would have fallen 3.13 percent. Revenue would be down 4.31 percent from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
EPS Estimate | 4.12 | 3.36 | 4.73 | 4.07 |
EPS Actual | 4.42 | 3.74 | 4.86 | 4.15 |
Stock Performance
Over the past 52-week period, shares of Allergan have declined 1.74 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The most common rating from analysts on Allergan stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Allergan's Q3 conference call is scheduled to begin at 8:30 a.m. ET and can be accessed here: https://edge.media-server.com/m6/p/sf2mavf6
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.